oncotice
merck sharp & dohme (israel - 1996) company ltd, israel - bcg strain - powder for solution for instillation - bcg strain 200 - 800 miu - bcg vaccine - bcg vaccine - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.
bcg vaccine powder for injection with diluent
sanofi-aventis australia pty ltd - mycobacterium bovis (bacillus calmette and guerin (bcg) strain), quantity: 1.5 mg - injection, powder for - excipient ingredients: monosodium glutamate monohydrate - bcg vaccine is recommended for active immunisation in high risk groups. the nhmrc recommendation for bcg vaccination are: bcg is recommended for use in 3 groups of infants: . aboriginal and torres strait islander neonates in regions of high incidence; . neonates born to patients with leprosy; . children under the age of 5 years who will be travelling to live in countries of high tuberculosis prevalence for long periods. bcg vaccination should be considered for the following children and adolescents: .neonates who will be living in a household which includes immigrants or visitors recently arrived from countries of high prevalence (this also applies to neonates in families who have returned to visit the homes of relatives in countries of high prevalence); . children and adolescents aged less than 16 years who continue to be exposed to a patient with active tuberculosis, and where the child or adolescent cannot be placed on isoniazid therapy or the active case has organisms resistant to both isoniazid and rifam
bcg vaccine ajv
seqirus (nz) ltd - bacillus calmette-guerin 0.75 mg/ml (when reconstituted with diluted sauton ajv (danish strain 1331) (vaccine)) - suspension for injection - 0.75 mg/ml - active: bacillus calmette-guerin 0.75 mg/ml (when reconstituted with diluted sauton ajv (danish strain 1331) (vaccine)) excipient: monosodium glutamate asparagine citric acid monohydrate dibasic potassium phosphate ferric ammonium citrate glycerol magnesium sulfate water for injection - active immunisation against tuberculosis
verity-bcg powder for suspension
verity pharmaceuticals inc. - bacillus calmette-guÉrin (bcg) - strain russian bcg-i - powder for suspension - 40mg - bacillus calmette-guÉrin (bcg) - strain russian bcg-i 40mg
bcg medac, powder and solvent for intravesical suspension
medac gesellschaft für klinische spezialpräparate mbh - bacillus calmette guérin (bcg) - powder and solvent for intravesical suspension - unknown - other immunostimulants; bcg vaccine
bcg vaccine ssi %v/v pdr+solv for susp for inj
statens serum institute - mycobacterium bovis (bcg) stam 1331 - pdr+solv for susp for inj - %v/v - tuberculosis vaccines
bcg vaccine powder lyophilized for solution for injection
serum institute of india pvt. ltd. - bcg vaccine(bacillus calmette guerin strain) - powder lyophilized for solution for injection - between 2x10^5 and 8x10^5 cfu/0,1ml
bcg vaccine ssi powder and solvent for suspension for injecti
statens serum institut 5 artillerivej dk 2300 copenhagen s denmark - bcg vaccine danish strain 1331 - powder and solvent for suspension for injecti - 2-8 x 105 cfu - bacterial vaccines: tuberculosis vaccines
bcg vaccine ajv
aj vaccines a/s - mycobacterium bovis (bcg) stam 1331 - powder and solvent for suspension for injection - 0 colony forming unit(s)/millilitre - tuberculosis vaccines; tuberculosis, live attenuated
bcg vaccine ajv powder and solvent for suspension for injection
dksh singapore pte. ltd. - live attenuated mycobacterium bovis (bcg) danish 1331 - injection, powder, for solution - 0.75 mg/ml - live attenuated mycobacterium bovis (bcg) danish 1331 0.75 mg/ml